Summary
Edwards Lifesciences Corporation (EW) demonstrated solid performance in its fiscal year ending December 31, 2025, with total net sales reaching $6.1 billion, an increase of 11.5% year-over-year, primarily driven by strong sales in Transcatheter Aortic Valve Replacement (TAVR) and significant growth in Transcatheter Mitral and Tricuspid Therapies (TMTT). Despite revenue growth, net income from continuing operations saw a decrease due to increased operational expenses, personnel costs, one-time charges related to investment impairments, and litigation expenses. The company continues to invest heavily in research and development, allocating 18% of net sales to innovation, particularly in its structural heart programs. Key strategic developments include FDA approval for the SAPIEN 3 platform for asymptomatic severe aortic stenosis patients and successful clinical trial results supporting its mitral and tricuspid therapies. These advancements highlight the company's commitment to expanding its portfolio and solidifying its leadership in the structural heart disease market.
Financial Highlights
52 data points| Revenue | $6.07B |
| Cost of Revenue | $1.33B |
| Gross Profit | $4.73B |
| R&D Expenses | $1.08B |
| SG&A Expenses | $2.09B |
| Operating Income | $1.26B |
| Net Income | $1.07B |
| EPS (Basic) | $1.84 |
| EPS (Diluted) | $1.83 |
| Shares Outstanding (Basic) | 584.80M |
| Shares Outstanding (Diluted) | 585.80M |
Key Highlights
- 1Net sales increased by 11.5% to $6.1 billion in 2025, driven by strong performance in TAVR and TMTT segments.
- 2TAVR remains the largest revenue driver, accounting for 74% of net sales in 2025.
- 3TMTT segment experienced substantial growth at 56.4%, indicating increasing market penetration and adoption of new therapies.
- 4Research and development expenses increased by 2% to $1.079 billion, representing approximately 18% of net sales, underscoring a commitment to innovation.
- 5The company received FDA approval for the SAPIEN 3 platform for asymptomatic severe aortic stenosis patients, expanding market access.
- 6Significant litigation and intellectual property expenses of $325.4 million impacted net income, a key factor for investor consideration.
- 7Edwards Lifesciences returned approximately $884.7 million to shareholders through share repurchases in 2025.